CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia
Background: Chronic myeloid leukemia (CML) is classified as a subtype of myeloproliferative neoplasm, and bone marrow flow cytometry does not reveal any specific immunophenotype. Interestingly, aberrant expression of cluster of differentiation (CD) markers such as CD56 and CD38 has been observed on...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-11-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024154965 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846167051536695296 |
|---|---|
| author | Panpan Huang Cuiping Zhang Aimei Zhang Ju Mao Gan Liu Chaojie Hu Huaiping Zhu |
| author_facet | Panpan Huang Cuiping Zhang Aimei Zhang Ju Mao Gan Liu Chaojie Hu Huaiping Zhu |
| author_sort | Panpan Huang |
| collection | DOAJ |
| description | Background: Chronic myeloid leukemia (CML) is classified as a subtype of myeloproliferative neoplasm, and bone marrow flow cytometry does not reveal any specific immunophenotype. Interestingly, aberrant expression of cluster of differentiation (CD) markers such as CD56 and CD38 has been observed on neutrophils in CML patients. Therefore, we investigated the abnormal expression of CD56 and CD38 in CML neutrophils to explore their diagnostic value in identifying CML through flow cytometry. Methods: We have developed a multi-parameter flow cytometry assay to identify aberrant immunophenotypes in CML neutrophils among bone marrow nucleated cells. Results: Compared to healthy donors and patients with a reactive neutrophilia or other hematological malignancies, the percentage of CD56briCD38+ neutrophil subsets in CML patients exhibits a distinctive increase (cut-off value, 2.0 %). The specificity and sensitivity associated with the learning cohort (168 samples) were 90.8 % and 84.9 %, respectively, while in the validation cohort (194 samples), they were 90.7 % and 84.7 %. The accumulation of CD56briCD38+ neutrophil subsets, which demonstrate are abnormal characteristics, is independent of the neutrophil count, BCR/ABL1 fusions and risk stratification but associated with blast cells immunophenotype. Moreover, this increase disappears in CML patients after treatment with tyrosine kinase inhibitors when the curative effect was satisfactory. Conclusions: We conclude that an increase in the proportion of CD56briCD38+ neutrophil subsets exceeding 2.0 % of total neutrophils serves as a highly sensitive and specific flow cytometry marker, enabling rapid and accurate identification of CML. |
| format | Article |
| id | doaj-art-7a6eba9e626843b5911ccfabf72c1fb0 |
| institution | Kabale University |
| issn | 2405-8440 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj-art-7a6eba9e626843b5911ccfabf72c1fb02024-11-15T06:12:50ZengElsevierHeliyon2405-84402024-11-011021e39465CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemiaPanpan Huang0Cuiping Zhang1Aimei Zhang2Ju Mao3Gan Liu4Chaojie Hu5Huaiping Zhu6Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, PR China; Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei, PR ChinaDepartment of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, PR China; Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei, PR ChinaDepartment of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, PR China; Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei, PR ChinaDepartment of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, PR China; Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei, PR ChinaDepartment of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, PR China; Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei, PR ChinaDepartment of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, PR China; Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei, PR China; Corresponding author. Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, PR China.Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, PR China; Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei, PR China; Corresponding author. Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, PR China.Background: Chronic myeloid leukemia (CML) is classified as a subtype of myeloproliferative neoplasm, and bone marrow flow cytometry does not reveal any specific immunophenotype. Interestingly, aberrant expression of cluster of differentiation (CD) markers such as CD56 and CD38 has been observed on neutrophils in CML patients. Therefore, we investigated the abnormal expression of CD56 and CD38 in CML neutrophils to explore their diagnostic value in identifying CML through flow cytometry. Methods: We have developed a multi-parameter flow cytometry assay to identify aberrant immunophenotypes in CML neutrophils among bone marrow nucleated cells. Results: Compared to healthy donors and patients with a reactive neutrophilia or other hematological malignancies, the percentage of CD56briCD38+ neutrophil subsets in CML patients exhibits a distinctive increase (cut-off value, 2.0 %). The specificity and sensitivity associated with the learning cohort (168 samples) were 90.8 % and 84.9 %, respectively, while in the validation cohort (194 samples), they were 90.7 % and 84.7 %. The accumulation of CD56briCD38+ neutrophil subsets, which demonstrate are abnormal characteristics, is independent of the neutrophil count, BCR/ABL1 fusions and risk stratification but associated with blast cells immunophenotype. Moreover, this increase disappears in CML patients after treatment with tyrosine kinase inhibitors when the curative effect was satisfactory. Conclusions: We conclude that an increase in the proportion of CD56briCD38+ neutrophil subsets exceeding 2.0 % of total neutrophils serves as a highly sensitive and specific flow cytometry marker, enabling rapid and accurate identification of CML.http://www.sciencedirect.com/science/article/pii/S2405844024154965Flow cytometryChronic myeloid leukemiaImmunophenotypeCD56CD38 |
| spellingShingle | Panpan Huang Cuiping Zhang Aimei Zhang Ju Mao Gan Liu Chaojie Hu Huaiping Zhu CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia Heliyon Flow cytometry Chronic myeloid leukemia Immunophenotype CD56 CD38 |
| title | CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia |
| title_full | CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia |
| title_fullStr | CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia |
| title_full_unstemmed | CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia |
| title_short | CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia |
| title_sort | cd56bricd38 as a novel neutrophil specific marker in chronic myeloid leukemia |
| topic | Flow cytometry Chronic myeloid leukemia Immunophenotype CD56 CD38 |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024154965 |
| work_keys_str_mv | AT panpanhuang cd56bricd38asanovelneutrophilspecificmarkerinchronicmyeloidleukemia AT cuipingzhang cd56bricd38asanovelneutrophilspecificmarkerinchronicmyeloidleukemia AT aimeizhang cd56bricd38asanovelneutrophilspecificmarkerinchronicmyeloidleukemia AT jumao cd56bricd38asanovelneutrophilspecificmarkerinchronicmyeloidleukemia AT ganliu cd56bricd38asanovelneutrophilspecificmarkerinchronicmyeloidleukemia AT chaojiehu cd56bricd38asanovelneutrophilspecificmarkerinchronicmyeloidleukemia AT huaipingzhu cd56bricd38asanovelneutrophilspecificmarkerinchronicmyeloidleukemia |